Цефтриаксон-Джодас

Quick links

Choose a section

Quick links to important sections

Advertisements

Цефтриаксон-Джодас

Selected form

Advertisements
Advertisements

Overview of Цефтриаксон-Джодас

Quick Facts

Property Description
Active ingredient Ceftriaxone (as Ceftriaxone Sodium)
Form Sterile powder for injection or infusion
Pharmacological class Third-Generation Cephalosporin Antibiotic
Common use Treating a variety of serious bacterial infections
Origin Semisynthetic

## What Type of Medicine is Цефтриаксон-Джодас?

Цефтриаксон-Джодас is a powerful, prescription-only antibiotic used to combat serious bacterial infections. The active substance, Ceftriaxone, is medically recognized as a third-generation cephalosporin. This classification highlights the drug's role as an advanced antimicrobial agent.

Ceftriaxone has broad activity against many common and resistant bacteria, a key differentiator from older antibiotics. It is typically utilized in hospital or clinical settings due to the severity of the infections it addresses. This makes the medicine a specialized option reserved for patients who require highly effective, rapid-onset treatment for established bacterial disease.

## Composition and Form: What is it Made of?

The medicine is supplied as a sterile, pale yellowish powder that is classified as a semisynthetic compound. The active component is Ceftriaxone (as the sodium salt), and it is a single-ingredient formulation.

Because the drug is poorly absorbed when taken by mouth, it must be given via the parenteral route (as an injection into a muscle or vein). This necessity for direct administration ensures optimal concentration and effectiveness in the bloodstream. The mechanism of action is bactericidal, meaning it actively kills bacteria by preventing them from building their protective cell walls.

## The General Purpose of Ceftriaxone

The general purpose of Ceftriaxone is to achieve swift and definitive control over susceptible bacterial pathogens in the body. Its efficacy is utilized in treating serious systemic infections. This function is crucial when the rapid clearance of bacterial infection is necessary for patient recovery, but it is important to note that the medicine is ineffective against viral or fungal diseases.

Advertisements

What side effects are possible with Цефтриаксон-Джодас?

Possible Side Effects and Safety Information

This information reflects the adverse reactions and safety constraints formally documented in regulatory sources (e.g., FDA, EMA labels) and is not intended as medical advice or dosing instruction.

Common and Expected Adverse Reactions

Side effects reported as common (affecting up to 1 in 10 patients) typically include temporary, minor changes in blood tests, such as increased white blood cells (eosinophilia) or platelets (thrombocytosis), as well as decreased white blood cells (leukopenia). Gastrointestinal issues like diarrhea and transient elevations of liver enzymes (AST/ALT) are also commonly observed. Localized reactions, such as pain or tenderness at the injection site, are also frequent.

Serious Adverse Reactions and Safety Warnings

While generally rare, certain serious or clinically significant adverse reactions have been documented:

  • Severe Hypersensitivity: Immediate, life-threatening allergic reactions (anaphylaxis) and serious skin reactions (e.g., Stevens-Johnson syndrome, Toxic Epidermal Necrolysis) have been reported.
  • C. difficile Colitis: The medication can cause Clostridioides difficile-associated diarrhea (CDAD), which may range in severity from mild diarrhea to fatal colitis, and can occur during or after treatment.
  • Blood Disorders: Severe blood cell problems, including hemolytic anemia, have been reported in both adults and children.
  • Gallbladder and Kidney Stones: Formation of ceftriaxone-calcium precipitates (pseudolithiasis) in the gallbladder, as well as kidney stones (urolithiasis), has been documented.

Critical Safety Restrictions (The Calcium Interaction)

Ceftriaxone must not be administered with any intravenous solutions containing calcium, including continuous infusions or parenteral nutrition, due to the regulatory risk of fatal ceftriaxone-calcium precipitation in the lungs and kidneys. This restriction is especially critical and absolute in neonates (infants less than 28 days old), where this simultaneous use is strictly prohibited. Use in jaundiced newborns is also contraindicated due to the risk of kernicterus.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

This section describes the officially documented manifestations and required emergency actions for Ceftriaxone overexposure, based strictly on government regulatory documents.


Overdose Manifestations and Risks

Scope Element Official Regulatory Documentation
Documented overdose presentations Gastrointestinal disturbances, including nausea, vomiting, and diarrhoea.
Physiological systems affected Gastrointestinal, Hepatobiliary, Renal, and Central Nervous System.
Dose-related or exposure-related factors High doses increase the risk of precipitation. Accumulation in patients with combined hepatic and severe renal impairment increases toxicity risk.
Population-specific overdose notes Pediatric patients are more susceptible to biliary precipitates. Severe renal impairment increases the risk of CNS toxicity (convulsions) due to prolonged drug half-life.

Required Emergency Response

Classification Element Official Regulatory Documentation
Immediate actions required Treatment is symptomatic and supportive. No specific antidote is known, and drug removal is not effective through haemodialysis or peritoneal dialysis.
When to seek medical help Seek immediate medical attention for suspected overdose. Urgent medical services must be contacted immediately if severe neurological symptoms (e.g., convulsions, inability to wake) or signs of obstruction (e.g., severe abdominal or flank pain) are present.

Official Overdose Profile Summary

Regulatory documents define the Ceftriaxone overdose profile as an emergency situation characterized by acute gastrointestinal symptoms and the risk of severe complications, including physical precipitation within the biliary and urinary systems, potentially leading to post-renal acute renal failure. Severe neurological effects, such as convulsions, are also documented consequences of high exposure, especially in compromised patients. Since treatment is limited to supportive care and no specific antidote exists, authorities mandate that patients seek immediate medical attention upon suspicion of overexposure.

Advertisements

Therapeutic Uses of Цефтриаксон-Джодас

Цефтриаксон-Джодас is commonly used across domains where additional symptomatic support is needed for susceptible bacterial infections, particularly those that require focused, systemic intervention.

The medication is applied in addressing severe conditions such as bacterial meningitis, sepsis, pneumonia, bone and joint infections, complicated urinary tract infections (pyelonephritis), and specific sexually transmitted infections like gonorrhea. It is also relevant when supportive symptom management is appropriate before certain types of surgery.

Therapeutic Benefit and Symptom Management

The primary therapeutic benefit is supportive symptom management in acute situations, which helps to manage acute, disruptive symptoms. It is applied in addressing symptom clusters related to systemic imbalance, such as intense fever and chills, as well as symptoms of deep-seated inflammation, including severe pain and swelling. This supportive management is relevant in contexts involving heightened systemic burden.

The medication's use may assist with maintaining functional stability during severe episodes by reducing the overall symptom load and contributes to improved comfort.


Quick Fact: Symptom Support

Therapeutic Use Frame Primary Therapeutic Benefit
Conditions with Systemic Discomfort Supports the easing of pronounced symptoms like fever and chills.
Conditions Involving Localized Inflammation Helps manage pain and swelling in deep-seated infections.
Acute Symptomatic Episodes Contributes to maintaining comfort and functional stability during severe periods.

Regulatory References

  1. Ceftriaxone Injection: MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

This medicine is an antibiotic intended for use by adult and pediatric patients who do not have documented contraindications to its use. The official regulatory documents strictly define the populations who must not receive it due to significant risks.

Populations Who Must Not Use Цефтриаксон-Джодас (Contraindicated)

Contraindication Affected Population Reason for Restriction
Allergy Patients with known hypersensitivity to ceftriaxone, any cephalosporin, or a history of severe allergic reaction to any other beta-lactam antibacterial (e.g., penicillins). Risk of life-threatening allergic reactions.
IV Calcium Neonates (le 28 days) requiring intravenous calcium-containing solutions (including continuous infusions like parenteral nutrition). Risk of fatal ceftriaxone-calcium precipitation in the lungs and kidneys.
Neonatal State Premature neonates up to a postmenstrual age of 41 weeks, and full-term neonates with hyperbilirubinemia (jaundice). Risk of bilirubin encephalopathy (kernicterus) due to drug displacing bilirubin from albumin.
Diluent Use Any patient where the solution is reconstituted with lidocaine for intravenous administration. Intravenous use of lidocaine-containing solutions is strictly prohibited.

Other Eligibility Rules

For patients older than 28 days, ceftriaxone and calcium-containing solutions must not be mixed or administered simultaneously, though they may be given sequentially if the infusion line is thoroughly flushed between administrations. Patients with combined severe renal and hepatic dysfunction should be closely monitored, and the maximum daily dose may be restricted.

Advertisements

What should I know about interactions with other medicines?

The official regulatory interaction profile for Цефтриаксон-Джодас is structured around the profound physical incompatibility with calcium-containing intravenous solutions. This interaction creates the risk of fatal precipitation and is therefore strictly contraindicated in neonates (patients aged 28 days or younger) as explicitly stated by official health authorities.

For all patients aged 28 days or older, Цефтриаксон-Джодас and calcium-containing solutions must not be administered simultaneously, even when using separate intravenous lines. Sequential administration in this older group is permitted only if the infusion line is thoroughly flushed between administrations with a compatible fluid.

Additionally, the drug is contraindicated for intravenous administration when reconstituted with Lidocaine. A separate pharmacodynamic interaction is documented with oral anticoagulants, such as Warfarin, where co-administration may increase the anticoagulant effect, raising the official risk of bleeding.

In vitro studies have shown antagonistic effects when combined with Chloramphenicol. Finally, physical incompatibilities are documented with several other intravenous agents, including Aminoglycosides, Vancomycin, and Fluconazole, which must not be mixed in the same line.

Advertisements

Mechanism of Action

How Цефтриаксон-Джодас Works

Цефтриаксон-Джодас is a beta-lactam molecule that acts via a selective enzymatic inhibition mechanism on biological processes required for bacterial survival. The resulting mechanism is bactericidal, meaning it actively causes the destruction of the pathogen.


Irreversible Inhibition of Bacterial Cell Wall Synthesis

The molecule's action focuses on Penicillin-Binding Proteins (PBPs), which are bacterial enzymes responsible for constructing the rigid peptidoglycan structure. Ceftriaxone irreversibly inhibits these enzymes by binding to them, preventing the final, crucial step of peptidoglycan cross-linking. This failure to assemble a stable cell wall structure initiates the lethal cascade that follows.


Cascade Leading to Cellular Lysis and Microbial Elimination

The structural vulnerability caused by PBP inhibition means the bacterial cell cannot withstand its high internal pressure. This triggers internal bacterial autolytic enzymes (autolysins), which results in the lysis (rupture) of the cell. This dual process of structural failure and autodigestion culminates in the destruction of susceptible bacterial populations at the affected site.

Advertisements

Dosage and Administration Information

How to use Цефтриаксон-Джодас — Official Administration Guidelines

This medication is a sterile powder intended for parenteral administration via either intravenous (IV) or intramuscular (IM) injection. It must be prepared and administered precisely as outlined in established protocols to ensure safety and effectiveness.

Administration and Dosing

Route Standard Adult Dose & Frequency Max Daily Dose Administration Time/Note
IV Infusion 1 g to 2 g once daily or divided q12 h 4 g (max) Administer over approximately 30 minutes.
Slow IV Injection 1 g to 2 g once daily or divided q12 h 4 g (max) Administer over 5 minutes.
Deep IM Injection 1 g to 2 g once daily or divided q12 h 4 g (max) 1 g maximum per single injection site.

Preparation and Procedural Steps

  • Reconstitution: The dry powder must be reconstituted using the appropriate sterile diluent before administration. For IM injection, reconstitution is typically done with 1% Lidocaine Injection; this solution must not be administered intravenously. For IV administration, reconstitution and subsequent dilution must use specified compatible solutions, such as Sterile Water for Injection, 0.9% Sodium Chloride, or 5% Dextrose.
  • IV Infusion Dilution: For IV infusion, the initial solution must be further diluted to a final concentration to be infused over the 30-minute time period.
  • Age-Specific Rules: Doses for neonates (0–14 days) must be administered by IV infusion over 60 minutes to mitigate potential risks.
  • Critical Restriction: This medication must not be co-administered with any calcium-containing IV solutions or products, including by simultaneous infusion through a separate line, due to the risk of precipitation.
  • Dosage Adjustment: Patients with both significant hepatic and renal impairment should generally not receive more than 2 grams per day.
Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies for Ceftriaxone (Цефтриаксон-Джодас)


Research on Lower Respiratory and Skin Infections

Research has explored the use of Ceftriaxone in conditions like lower respiratory tract infections, such as pneumonia, and infections involving the skin and underlying soft tissues. These are conditions often characterized by fluctuating or episodic manifestations of symptoms. Studies were conducted during periods of increased symptom activity and focused on episodes where symptoms become more noticeable.

The findings indicate patterns related to outcomes reflecting daily functioning or activity level and outcomes related to physical discomfort. In general, studies observed that the use of this treatment was associated with specific changes measured during the study period for these common infection types. Evidence contributes to understanding symptom patterns and how patients reported their experience during the course of the research.

It is important to understand that the results apply only to the populations studied in the specific research. Comparative evidence against other antibiotic treatment options remains insufficient in certain areas, meaning the precise role of this agent versus alternatives is still emerging. Studies help show what has been observed so far, but research provides context but not individual predictions.


Research Exploring Serious Systemic Infections and Meningitis

Ceftriaxone was studied in the context of serious, acute infections, including bacterial septicemia (bloodstream infection) and meningitis (infection affecting the membranes around the brain and spinal cell). These are conditions associated with acute or disruptive episodes and involve treatment scenarios exploring short-term symptom changes in a critical care setting.

Studies explored how outcomes related to systemic or functional imbalance evolved in the observed populations in these critical settings. The evidence suggests patterns related to outcomes linked to inflammatory or irritative states. The data show patterns related to changes in the observed populations in specific, controlled research settings. While the findings describe group patterns, not personal outcomes, for specific types of serious infection, the evidence is limited for long-term recovery markers, and long-term effects are not fully established.


Studies in Specific Patient Groups and Other Conditions

Research has also examined the use of Ceftriaxone in conditions such as urinary tract infections and as a measure used in observational settings evaluating prevention in specific surgical scenarios. Studies for these conditions often monitored outcomes capturing phases of heightened symptom activity.

For newborns, research has observed that the drug may interact with high bilirubin levels, and its use has been noted as a potential concern in premature and certain neonatal infants. Research is ongoing to better understand the optimal use and long-term outcomes across all age groups, especially since evidence quality varies across studies and subgroup findings are uncertain for certain populations with other medical concerns. Evidence highlights what is known — and what is still uncertain.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Цефтриаксон-Джодас (FAQ)

Q: What is Цефтриаксон-Джодас used for?

A: Цефтриаксон-Джодас is an antibiotic used to treat a variety of bacterial infections, including those of the lower respiratory tract, skin and skin structure, urinary tract, pelvis, bone, and joints. It may also be used for certain surgical prophylaxis and bacterial meningitis, as determined by a healthcare provider.

Q: Can I stop taking Цефтриаксон-Джодас once I feel better?

A: It is generally advised that patients complete the full course of antibiotic therapy as prescribed by their doctor, even if symptoms appear to improve early. Stopping the medication too soon may lead to the return of the infection and could contribute to the development of antibiotic-resistant bacteria.

Q: Are there any foods or drinks I should avoid while taking this medication?

A: There are typically no specific dietary restrictions related to food or non-alcoholic beverages while receiving Цефтриаксон-Джодас. However, patients should always consult their healthcare provider for specific dietary guidance, especially regarding any known drug-food interactions.

Advertisements

How should Цефтриаксон-Джодас be stored and disposed of?

How to Store and Dispose of Ceftriaxone for Injection

The storage of unreconstituted Ceftriaxone powder must comply with regulatory requirements, specifically by maintaining a Controlled Room Temperature of 20 C to 25 C (68 F to 77 F) and ensuring the vials are protected from light. The medicine must be kept out of the sight and reach of children.

Once reconstituted, the solution's stability is limited; it is typically stable for only 24 hours at room temperature or for an extended period, such as 3 to 10 days, when refrigerated.

A mandatory handling rule dictates that the product must not be simultaneously mixed with calcium-containing solutions. Any unused product or waste material resulting from the administration must be disposed of according to local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Цефтриаксон-Джодас found in:

A-Z Index: